David Dornan - 15 Feb 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
15 Feb 2025
Net transactions value
-$2,789
Form type
4
Filing time
19 Feb 2025, 16:15:07 UTC
Previous filing
20 Feb 2024
Next filing
18 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +9,375 9,375 15 Feb 2025 Direct F1
transaction ELEV Common Stock Tax liability $2,789 -4,152 -44% $0.6717 5,223 15 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Restricted Stock Unit Options Exercise $0 -9,375 -25% $0.000000 28,125 15 Feb 2025 Common Stock 9,375 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

David Dornan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 The RSUs do not expire; they either vest or are canceled prior to the vesting date.